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Abstract 
 
Background 
Patients with motor neurone disease (MND) suffer from reduced motility and 
strength of the neck muscles over time.  This commonly results in difficulties 
with correct positioning for communicating, eating and breathing.  There are a 
number of neck braces which available for MND patients, however they are 
inadequate for the majority of MND patients, and a new collar is set to be 
designed.  This paper conducts a brief analysis of the potential cost 
effectiveness of such a collar. 
 
Methods 
A cost-utility analysis was undertaken using a simple three state Markov 
model of disease progression.  The key input to this model were utilities from 
a small health valuation survey based around scenarios describing MND and 
the associated symptoms and limitation relating to reduced neck motility and 
strength.  A scenario sensitivity analysis was used to identify the price at 
which new neck braces could be cost-effective given different effets on uptake 
and effectiveness. 
 
Results 
Four scenarios were examined that examined different impacts on rates of 
use of a neck brace and effectiveness of the new neck brace.  For moderate 
effectiveness and no impact on non-use the maximum annual incremental 
collar cost to the NHS, using a funding threshold of £20,000 per quality 
adjusted life year, was £720.  Adjusting this scenario for a large effect 
increases the maximum allowable cost to £960.  Altering these two scenarios 
to include a large impact on rates of non-use produced maximum allowable 
costs of £800 and £1,040, respectively, 
 
Conclusions 
Our analysis suggests that there is considerable scope for a new neck brace 
for MND patients with moderate and severe neck pain to represent a cost 
effective use of NHS resources.  Even with a brace costing around £1,000, it 
is possible that it will be cost-effective.  However, these results should be 
interpreted with great caution:  the potential brace has not yet reached the 
final design stage and although we do not assume in this analysis that it will 
prove adequate for all MND patients with neck weakness, we do assume that 
it provides a very substantial increase in adequacy rates (18% to 50% for 
moderate patients, and 0% to 30-50% for severe patients). 
 
Key words 
Motor neurone disease, cost-effectiveness analysis, neck brace, quality of life, 
product development. 
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Introduction 
 
MND has a prevalence of 6-8 / 100,000 in the UK population.  At any one time 
there are approximately 5,000 people living with the condition, and 
approximately 1,200 die due to MND per year.  The majority of individuals can 
expect an average life expectancy of between two and five years from 
symptom onset, with only 10 – 15% of people surviving for longer than 5 
years.  Based on limited data we estimate that approximately 38% of MND 
patients have moderate or severe neck pain and require a neck brace, 
although this proportion could be higher.   
 
MND is a degenerative disease affecting the motor neurones in which cellular 
injury and death of motor neurones causes increasing loss of the connection 
between the nervous system and the voluntary muscles.  In the majority of 
cases this is a rapidly disabling condition resulting in progressive paralysis.  
The affected person develops progressive weakness and wasting of the 
muscles controlling the limbs, bulbar function and respiration.   
 
Motility and strength of the neck muscles decreases over time and the patient 
is then unable to raise their head independently.  This commonly results in 
difficulties with correct positioning for communicating, eating and breathing.  
An adult human head weighs between 4.5 and 5kg, and when the neck 
muscles become weaker the patient is no-longer able to provide adequate 
support for their head.   
 
There are a number of neck braces which are used to varying extents by 
MND patients.  These braces can enhance the ability of a patient to carry out 
activities such as eating and communicating, can prevent pain caused by poor 
neck positioning, and can avoid the development of restricted movement.  
However these braces are inadequate for the majority of MND patients, and a 
new collar is set to be designed.  This paper conducts a brief analysis of the 
potential cost effectiveness of such a collar. 
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Methods 
 
In undertaking our economic analysis we have primarily followed the methods 
developed and used by the Multidisciplinary Assessment of Technology 
Centre for Healthcare (MATCH) collaboration (Cosh et al 2007, McAteer et al 
2007).  These methods describe a process by which potential devices can be 
evaluated in order to ascertain the likelihood that they will prove to be cost 
effective and economically viable.  The process involves five key stages: 
strategic considerations; clinical problem definition; headroom analysis; return 
on investment analysis; and further economic analysis.   
 
The ‘strategic considerations’ stage primarily involves manufacturer 
considerations and market characteristics and as such we have not 
addressed this stage.  The ‘clinical problem definition’ stage involves a 
statement of the proposed technology, a description of the relevant disease 
area, where the proposed technology fits in the disease process, estimates of 
disease prevalence and incidence, an analysis of current treatments and their 
cost effectiveness.  Because the proposed neck brace that is the subject of 
this project has not been specifically defined it has not been possible to make 
a precise statement of the technology.  However the disease context has 
been investigated and this has been particularly important because of the 
progressive nature of the disease in question.  This has formed the basis of 
the structure of the economic model that we have developed.  Also, we have 
discussed the current nature of neck braces for patients with MND – 
specifically that they are sub-optimal.  We found no papers investigating the 
cost effectiveness of existing braces.  Our data on the likely effectiveness of 
the proposed brace compared to current braces is uncertain – we are not sure 
of the proportion of patients for whom the proposed brace will be adequate, 
and we are not sure whether the proposed brace will lead to more patients 
who need a brace actually using one.  Therefore we have conducted scenario 
analysis around assumptions for these parameters. 
 
The next section of this report reports the ‘headroom analysis’ that we have 
undertaken for the proposed neck brace.  Essentially, this stage of the 
MATCH framework aims to quantify the maximum incremental cost that the 
new technology could be associated with in order to be classed as cost 
effective, given assumptions around the clinical effectiveness of the 
technology.  To conduct such an analysis it is necessary to estimate the 
quality of life impact in terms of quality adjusted life years (QALYs) associated 
with the new technology compared to current care.  Given an estimated QALY 
gain and a cost effectiveness threshold (for example £20,000 as suggested by 
the National Institute for Health and Clinical Excellence (NICE)) the allowable 
incremental cost of the new technology can be estimated. 
 
We have not addressed the ‘return on investment’ and ‘further economic 
analysis’ stages of the MATCH framework.  These stages involve estimating 
the revenue and profit associated with the proposed technology, and 
conducting further sensitivity analysis to confirm the likely value of investment.  
These stages cannot be completed without finalised specific details about the 
technology because production costs need to be estimated.      
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Model Design 
 
A simple 3-state Markov model was developed in order to assess the cost 
effectiveness of the potential new neck collar.  The structure of the model 
follows a simplified structure of MND and neck weakness progression.  The 
structure of the model is shown in the following diagram. 
 
 
Figure 1:  Markov model 
 
 
We assume that a patient enters the model in a state of moderate MND with 
moderate neck weakness.  The model does not include patients with mild 
MND because it is assumed that the new neck collar will only be a relevant 
treatment choice for those patients with moderate or worse neck weakness – 
we assume that for mild MND patients a beanie collar is adequate. 
 
Figures from the Dementias & Neurodegenerative Diseases Research  
Network (DeNDRoN) suggest that 10-15% of MND patients survive for greater 
than 5 years from symptom onset.  We took the mid-point of this estimate 
(12.5%) and applied a mortality rate in the model such that 87.5% of patients 
are dead 4 years after entering the model.  We used a 4 year time-point rather 
than 5 years because we assume that patients spend on average 1 year in 
mild MND, and patients only enter the model when they have moderate 
disease.   We assume that patients spend on average half of this 4-year time 
period in moderate MND with moderate neck weakness, and half of this time 
in severe MND with severe neck weakness.  Given that we estimate that 
12.5% of patients will not have died after 4 years, we also assume that 12.5% 
of patients will not have progressed to severe MND after 2 years.  Thus, we 
apply a progression rate in the model such that 87.5% of patients will have 
Moderate 
MND/ 
moderate neck 
weakness 
 
Severe MND/ 
severe neck 
weakness 
 
 
Death 
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progressed to severe MND with severe neck weakness after 2 years.  We use 
a 1-year cycle length in the model. 
 
We assume that the neck collar does not alter disease progression.  However, 
within the moderate and severe health states different possible outcomes 
exist – a patient can either be wearing an adequate brace; wearing an 
inadequate brace; or wearing no brace despite the fact that one is needed.  
This is where a more effective brace will provide health benefits.  Therefore, 
within the moderate and severe health states a decision tree defines the 
outcomes experienced by the modelled patient cohort.  The decision tree is 
illustrated in the diagram below.  The effectiveness estimates that inform this 
decision tree are discussed in the following section. 
 
The decision tree dictates what proportion of patients are using an adequate, 
inadequate or no brace for moderate and severe health states.  We assume 
that once allocated to one of these outcomes, the patient does not move into 
a different collar-specific state, i.e., if they are in the moderate disease health 
state and their collar is inadequate, there is no chance that their collar will 
become adequate in the following cycle.  Hence, the only way in which a 
patient will move out of this state is if they die, or if they transition to severe 
disease, at which point they move through the severe state decision tree 
which determines whether their neck collar will be adequate, inadequate, or 
whether they wear no collar. 
 
For each decision tree outcome within the moderate and severe health states 
a quality of life score and cost is applied.  Costs and quality adjusted life years 
(QALYs) are discounted at annual rate of 3.5%.  The model is run until 
everyone in the modelled cohort has entered the death state. 
 
 
Figure 2:  Within-state decision tree 
 
 
 
Effectiveness 
 
The planned neck collar has not yet reached the final design stage, and 
therefore the clinical benefits it may bring are assumptions in scenarios which 
provide an illustration of the potential cost effectiveness of the new neck 
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collar.  The effectiveness of the new collar is measured in two ways which are 
included in the economic model, described below: 
 
• Increase in the proportion of MND patients who use a collar when one 
is needed.  Because existing collars are not adequate for the majority 
of MND patients a significant proportion of patients who need a collar 
do not use one.  We consider two possibilities with regard to the impact 
of the new collar on this assumption: 
 
− The new collar has no impact on the proportion of MND patients 
who use a collar when one is needed. 
 
− The new collar encourages all MND patients who need a collar to 
use one. 
 
• Increase in the proportion of MND patients who use a collar for whom 
their collar is adequate.  Because existing collars are sub-optimal for 
many patients, the key effectiveness benefit of the proposed new collar 
is that it will provide adequate neck support for more patients, which 
will be associated with an increased quality of life. 
 
In the table below the effectiveness scenarios that we have considered in our 
cost effectiveness analysis are presented. 
 
 
Table 1:  Scenarios considered in the cost effectiveness analysis 
 
 
 
 
Scenario 1 
Current situation Forecast situation (with 
new collar) 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
% that use 
collar given 
need 
81% 100% 81% 100% 
% for whom 
collar is 
adequate 
18% 0% 50% 30% 
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Table 1 (cont...):  Scenarios 
 
 
 
 
Scenario 2 
Current situation Forecast situation (with 
new collar) 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
% that use 
collar given 
need 
81% 100% 81% 100% 
% for whom 
collar is 
adequate 
18% 0% 50% 50% 
 
 
 
 
Scenario 3 
Current situation Forecast situation (with 
new collar) 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
% that use 
collar given 
need 
81% 100% 100% 100% 
% for whom 
collar is 
adequate 
18% 0% 50% 30% 
 
 
 
 
Scenario 4 
Current situation Forecast situation (with 
new collar) 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
Moderate 
MND / 
Moderate 
neck 
weakness 
Severe MND 
/ Severe 
neck 
weakness 
% that use 
collar given 
need 
81% 100% 100% 100% 
% for whom 
collar is 
adequate 
18% 0% 50% 50% 
 
 
These scenarios highlight the key effectiveness benefits that we assume the 
new collar will bring.  The proportions presented in the ‘current situation’ cells 
reflect those seen in MND patients treated at the Royal Hallamshire Hospital, 
Sheffield.  Thus, currently it is estimated that 81% of moderate patients who 
need a neck collar use one, and for 18% of these patients their collar is 
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adequate.  100% of severe patients who need a collar use one, but in no 
cases are the collar adequate for the patient.   
 
In scenario 1 it is assumed that the new collar does not alter the proportion of 
MND patients who use a collar, but the proportion for whom the collar is 
adequate increases from 18% and 0% for moderate and severe patients 
respectively, to 50% and 30%.  Hence it is not assumed that the new collar 
will be adequate for all patients because this may be overly optimistic, but 
adequacy rates are increased appreciably.  Scenario 2 is identical to scenario 
1, except it is assumed that adequacy rates increase to 50% for both 
moderate and severe patients. 
 
Scenario 3 is the same as scenario 1, except in this scenario it is assumed 
that the new collar will also have an impact on the proportion of MND patients 
who choose to use a collar, given that they need one.  Thus it is assumed that 
100% of moderate patients will use a collar in the forecast situation, compared 
to 81% in the current situation.  Similarly, scenario 4 is identical to scenario 2, 
except that it is assumed that the use rate among moderate patients will 
increase to 100% in the forecast situation. 
 
 
Quality of Life 
 
In order to estimate the potential cost effectiveness of the proposed new neck 
collar, utility scores need to be estimated for each of the health states 
included within the economic model.  MND utility scores are scarce in the 
existing literature, and certainly none exist which investigate the quality of life 
(QoL) scores associated with moderate and severe neck weakness with and 
without an adequate brace.  Therefore, in order to populate our model we 
constructed a health state quality of life elicitation questionnaire, which we 
administered to a small (n=14) convenience sample of the general population.  
The questionnaire included health state vignettes for 6 health states which we 
constructed with considerable input from clinical experts. 
 
The health states included were: 
 
Health State A:   Moderate MND with moderate neck weakness, with an 
adequate brace 
Health State B: Moderate MND with moderate neck weakness, with an 
inadequate brace 
Health State C:   Moderate MND with moderate neck weakness, with no 
brace 
Health State D:   Severe MND with severe neck weakness, with an adequate 
brace 
Health State E:   Severe MND with severe neck weakness, with an 
inadequate brace 
Health State F:   Severe MND with severe neck weakness, with no brace 
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Participants were asked to read the health state descriptions and to imagine 
they were experiencing each state.  They were then asked to complete the 
EQ-5D (Dolan 1997), the HUI3 (Feeney et al, 1995) and a Visual Analogue 
Scale (VAS) for each health state.  The results of the study were as follows: 
 
 
Table 2:  Health state elicitations 
 
Health 
State 
EQ5D HUI3 VAS 
Mean Lower 
CI 
Upper 
CI 
Mean Lower 
CI 
Upper 
CI 
Mean Lower 
CI 
Upper 
CI 
A 0.33 0.21 0.44 0.39 0.25 0.53 0.56 0.47 0.64 
B 0.11 -0.02 0.24 0.14 0.02 0.25 0.46 0.37 0.54 
C 0.07 -0.09 0.24 0.08 -0.05 0.20 0.42 0.33 0.50 
D -0.28 -0.40 -0.17 -0.18 -0.23 -0.13 0.31 0.22 0.40 
E -0.53 -0.61 -0.45 -0.26 -0.30 -0.21 0.18 0.11 0.26 
F -0.55 -0.62 -0.49 -0.26 -0.31 -0.22 0.14 0.06 0.22 
 
 
As can be seen from Table 3, there were substantial point estimate 
differences between several of the health states for each valuation instrument.  
In particular, there is a large difference between an adequate brace and an 
inadequate or no brace when a patient is in either moderate or severe disease 
– these differences were often statistically significant.  Also of note is that 
there were several negative scores elicited for severe disease when the EQ-
5D and HUI3 were used.  This implies that these states were valued as worse 
than death.  However, when the VAS was used no participants ranked any of 
the health states worse than death. 
 
In this paper, we present model results using the VAS quality of life scores.  
These represent a conservative estimate of QoL gain as the possible changes 
in utility values due to improvements in neck support are smallest using the 
VAS.  These scores are allocated to the decision tree outcomes experienced 
by the modelled cohort.   
 
 
Costs and comparators 
 
The only costs included in the analysis are the cost of collars.  Other resource 
use costs, such as physiotherapist appointments and GP consultations are 
not included due to a lack of data on neck-related MND appointments.  
Because it is likely that patients with better supported necks will require fewer 
appointments and consultations, our analysis will bias against the new neck 
collar.   
 
In addition, we do not know the likely cost of the new collar.  Hence the results 
presented here present a threshold analysis of the incremental cost allowable 
for the new collar, given its estimated clinical benefits.  We have included the 
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estimated costs of current collars, and so the estimated allowable incremental 
cost is over and above current collar costs (which are approximately £60 per 
annum, see Table 4). 
 
A number of neck braces are currently available to MND patients.  Initially 
patients use soft “beanie” style collars, which are generally popular as they 
are unobtrusive and comfortable to wear for extended periods of time.  As 
neck weakness increases a “Headmaster” or “Oxford” collar or similar will be 
prescribed.  These provide flexion control, but pressure sores can develop at 
the clavicles and under the chin if worn for long periods.  The final orthotic 
intervention is an “Aspen” or “Philadelphia” cervical collar, designed for 
trauma victims.  These collars hold the head rigidly, preventing all neck 
movement.  These collars tend to be unpopular with patients, as there is 
insufficient padding for users who have no neck muscle control.  See Box 1 
for an overview of the suitability of existing collars.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our model, we estimate an average annual collar cost for patients with 
moderate MND and moderate neck weakness, and for patients with severe 
MND and severe neck weakness.  Table 2 shows the assumptions upon 
which these estimates are based. 
 
 
 
 
 
Box 1:  Existing neck collars for MND patients 
 
The Beanie Collar 
These are comfortable and popular with patients, but become inadequate 
as neck weakness progresses.  These collars are sometimes used 
inappropriately. 
 
The Oxford Collar 
This is the only collar that has been designed specifically for MND patients.  
However it only restricts flexion of the head while supporting the head on 
the shoulders. This collar relies on the patient having control over the 
sideward tilting muscles of the neck. Patients with poor control of lateral 
movement due to their neck muscle weakness are not helped by this 
device. 
 
The Headmaster Collar 
This can be used for a greater degree of neck weakness however many 
patients get sore skin areas over the clavicle bones, with the weight of their 
head pressing onto their chest with no appropriate padding.  This can 
result in patients not wearing the collar because it is uncomfortable. It also 
does not provide any lateral support.   
 
The Philadelphia Collar 
This collar is hot and claustrophobic to wear, and with more severe neck 
muscle weakness pressures are created by the areas surrounding the chin 
and mandible.  There is inadequate padding for the clavicle area.  When 
muscle weakness is severe the head can fall forwards onto the collar 
resulting in excessive pressures on the chin and jaw leading to skin 
necrosis, or pressure onto the clavicle area which can result in severe 
discomfort. 
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Table 3:  Assumed collar pathways 
 
MND Stage Collar requirements Costs (£) 
Moderate MND, 
moderate neck 
weakness 
Year 1:  4 beanie collars 
(£10 each) 
Year 2:  1 Oxford collar 
(£89) 
Year 1:  £40 
Year 2:  £89 
Ave annual cost:  
£64.50 
Severe MND, severe 
neck weakness 
Year 1:  1 Oxford collar 
(£89) 
Year 2:  1 Philadelphia 
collar (£22) 
Year 1:  £89 
Year 2:  £22 
Ave annual cost:  
£55.50 
Note:  Cost of collars from the MND Association 
 
 
 
Results 
 
The model results presented below illustrate threshold analysis of the 
allowable incremental costs of the new collar if it is to be classed as cost 
effective, for each scenario modelled.  We used a cost effectiveness threshold 
of £20,000 as commonly used by the National Institute for Health and Clinical 
Excellence (NICE) in the UK.  This means that for each additional QALY 
gained, the incremental cost must be no more than £20,000.  If this criteria is 
satisfied a new collar would be very likely to be classed as cost effective by 
NICE and would therefore be reimbursed by the NHS. 
 
Scenario 1 
In this scenario we estimate that if the new collar had an annual incremental 
cost of £720 or less it would generate an incremental cost effectiveness ratio 
(ICER) of less than £20,000.   
The effect of incremental collar costs on the ICER: VAS
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Scenario 2 
In this scenario we estimate that if the new collar had an annual incremental 
cost of £960 or less it would generate an incremental cost effectiveness ratio 
(ICER) of less than £20,000.   
The effect of incremental collar costs on the ICER: VAS
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Scenario 3 
In this scenario we estimate that if the new collar had an annual incremental 
cost of £800 or less it would generate an incremental cost effectiveness ratio 
(ICER) of less than £20,000.   
The effect of incremental collar costs on the ICER: VAS
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Scenario 4 
In this scenario we estimate that if the new collar had an annual incremental 
cost of £1,040 or less it would generate an incremental cost effectiveness 
ratio (ICER) of less than £20,000.   
The effect of incremental collar costs on the ICER: VAS
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For ease of comparison, the results of our analysis are presented in Table 5. 
 
 
Table 5:  Results of the scenario analyses 
 
Scenario Scenario summary* Allowable annual incremental 
collar cost, producing ICER < 
£20,000 
1 Moderate impact on 
adequacy, no impact on use 
£720 
2 Large impact on adequacy, 
no impact on use 
£960 
3 Moderate impact on 
adequacy, large impact on 
use 
£800 
4 Large impact on adequacy, 
large impact on use 
£1,040 
*  For full details see Table 1. 
 
 
 
As expected, the largest allowable annual incremental collar costs are 
associated with scenarios 2 and 4, in which it is assumed that the new collar 
improves adequacy rates to 50% for both moderate and severe patients (as 
opposed to 30% for severe patients in scenarios 1 and 3).  Also as expected 
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the allowable annual incremental cost is higher in scenario 3 than in scenario 
1, and in scenario 4 compared to scenario 2.  This is expected because 
scenarios 1 and 3 and scenarios 2 and 4 are identical other than scenarios 2 
and 4 assuming that the new collar will increase the use of neck collars from 
81% to 100% in moderate patients (both sets of scenarios assume 100% use 
in severe patients, in line with current situation estimates).  
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Conclusions 
 
Our analysis suggests that there is considerable scope for a new neck brace 
for MND patients with moderate and severe neck pain to represent a cost 
effective use of NHS resources.  Even with a brace costing around £1,000, it 
is possible that it will be cost-effective.  However, these results should be 
interpreted with great caution:  the potential brace has not yet reached the 
final design stage and although we do not assume in this analysis that it will 
prove adequate for all MND patients with neck weakness, we do assume that 
it provides a very substantial increase in adequacy rates (18% to 50% for 
moderate patients, and 0% to 30-50% for severe patients). 
 
In addition, the results presented here are dictated importantly by the health 
state values that we have elicited from a small convenience sample, which 
provided us with substantial quality of life score differences for the different 
health states.  If the true differences between these health states was found to 
be much smaller (for example through a larger sample of MND patients), this 
would reduce the allowable annual incremental collar costs significantly.     
 
Despite these weaknesses, the results also include some conservative 
assumptions/estimates.  The estimates are based on the VAS health state 
valuation tool, which gave the smallest between health state differences.  
Therefore from this perspective the results presented are pessimistic.  In 
addition, no other resource use savings are included, which – assuming that a 
more suitable neck collar would reduce other resource use – also biases our 
results against the new collar.   
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